The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Immunotherapy and Prevention of Pancreatic Cancer
Open accessAbstract
Pancreatic cancer is the third leading cause of cancer mortality in the United States, recently surpassing breast cancer. A key component of pancreatic cancer’s lethality is its acquired immune privilege, which is driven by an immunosuppressive microenvironment, poor T-cell infiltration, and a low mutational burden. Although immunotherapies such as checkpoint blockade or engineered T cells have yet to demonstrate efficacy, a growing body of evidence suggests that orthogonal combinations of these and other strategies could unlock immunotherapy in pancreatic cancer. In this review, we will discuss promising immunotherapies currently under investigation in pancreatic cancer and provide a roadmap for the development of prevention vaccines for this and other cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 2×
“Immune checkpoint blockade seems to have minimal activity, and despite promising phase I data, whole cell therapeutic vaccines have demonstrated no effect in late stage trials [6,11,12].”
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“PDA has low baseline PD-1+ T-cell infiltration into the tumor [15,21] and a paucity of neoepitopes [17,22], both of which are predictive of response to PD-1 blockade in other solid tumors [23,24].”
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.-J., Cowey, C. L., Lao, C. D., Wagstaff, J., Schadendorf, D., Ferrucci, P. F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709684 · Cited by 5,357 · cited 1×
“For example, the combination of nivolumab and ipilimumab significantly improved survival compared to either monotherapy in melanoma [101], but the combination comes with the tradeoff of greater toxicity and greater expense.”
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Özdemir, B. C., Pentcheva-Hoang, T., Carstens, J. L., Zheng, X., Wu, C.-C., Simpson, T. R., Laklai, H., Sugimoto, H., Kahlert, C., Novitskiy, S. V., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.005 · Cited by 2,681 · cited 1×
“Early stage studies are beginning to demonstrate the therapeutic potential of modulating the stroma, although some controversy remains over whether stromal targeting is always beneficial [91,92].”
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Rhim, A. D., Oberstein, P. E., Thomas, D. H., Mirek, E. T., Palermo, C. F., Sastra, S. A., Dekleva, E. N., Saunders, T., Becerra, C. P., Tattersall, I. W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.021 · Cited by 2,085
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,860
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Self-citationCorrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
Royal, R. E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,257
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Initiative, A. P. C. G., Balachandran, V. P., Łuksza, M., Zhao, J. N., Makarov, V., Moral, J. A., Remark, R., Herbst, B., Askan, G., Bhanot, U., et al. (2017) · Nature · doi:10.1038/nature24462 · Cited by 1,191
Sherman, M. H., Yu, R. T., Engle, D. D., Ding, N., Atkins, A. R., Tiriac, H., Collisson, E. A., Connor, F., Van Dyke, T., Kozlov, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.007 · Cited by 1,158
Direct detection of early-stage cancers using circulating tumor DNA
Phallen, J., Sausen, M., Adleff, V., Leal, A., Hruban, C., White, J., Anagnostou, V., Fiksel, J., Cristiano, S., Papp, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan2415 · Cited by 1,119
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
Jiang, H., Hegde, S., Knolhoff, B. L., Zhu, Y., Herndon, J. M., Meyer, M. A., Nywening, T. M., Hawkins, W. G., Shapiro, I. M., Weaver, D. T., et al. (2016) · Nature Medicine · doi:10.1038/nm.4123 · Cited by 1,060
Dynamics of the immune reaction to pancreatic cancer from inception to invasion
Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0175 · Cited by 990
Self-citationToxicity and management in CAR T-cell therapy
Bonifant, C. L., Jackson, H. J., Brentjens, R. J., & Curran, K. J. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.11 · Cited by 885
Beatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
Ino, Y., Yamazaki-Itoh, R., Shimada, K., Iwasaki, M., Kosuge, T., Kanai, Y., & Hiraoka, N. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.32 · Cited by 849
Steele, C. W., Karim, S. A., Leach, J. D. G., Bailey, P., Upstill-Goddard, R., Rishi, L., Foth, M., Bryson, S., McDaid, K., Wilson, Z., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.014 · Cited by 845
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M. M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 814
Nywening, T. M., Wang-Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R. K., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 807
Lehtinen, M., Paavonen, J., Wheeler, C. M., Jaisamrarn, U., Garland, S. M., Castellsagué, X., Skinner, S. R., Apter, D., Naud, P., Salmerón, J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70286-8 · Cited by 704
Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies
Unger, J. M., Cook, E., Tai, E., & Bleyer, A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156686 · Cited by 665
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Self-citationDecreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Chang, M.-H., You, S.-L., Chen, C.-J., Liu, C.-J., Lee, C.-M., Lin, S.-M., Chu, H.-C., Wu, T.-C., Yang, S.-S., Kuo, H.-S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp288 · Cited by 635
Sanford, D. E., Belt, B. A., Panni, R. Z., Mayer, A., Deshpande, A. D., Carpenter, D., Mitchem, J. B., Plambeck-Suess, S. M., Worley, L. A., Goetz, B. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0525 · Cited by 613
Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4244 · Cited by 611
Posey, A. D., Schwab, R. D., Boesteanu, A. C., Steentoft, C., Mandel, U., Engels, B., Stone, J. D., Madsen, T. D., Schreiber, K., Haines, K. M., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.014 · Cited by 594
Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation
Lutz, E. R., Wu, A. A., Bigelow, E., Sharma, R., Mo, G., Soares, K., Solt, S., Dorman, A., Wamwea, A., Yager, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0027 · Cited by 550
Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Beatty, G. L., O’Hara, M. H., Lacey, S. F., Torigian, D. A., Nazimuddin, F., Chen, F., Kulikovskaya, I. M., Soulen, M. C., McGarvey, M., Nelson, A. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.029 · Cited by 514
Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Hingorani, S. R., Zheng, L., Bullock, A. J., Seery, T. E., Harris, W. P., Sigal, D. S., Braiteh, F., Ritch, P. S., Zalupski, M. M., Bahary, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9564 · Cited by 510
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
Self-citationWinograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459
Self-citationAgonistic CD40 Antibodies and Cancer Therapy
Vonderheide, R. H., & Glennie, M. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2064 · Cited by 414
Self-citationMoon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2627 · Cited by 404
Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70236-0 · Cited by 378
Jang, J.-E., Hajdu, C. H., Liot, C., Miller, G., Dustin, M. L., & Bar-Sagi, D. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.062 · Cited by 372
Zhang, Y., Velez-Delgado, A., Mathew, E., Li, D., Mendez, F. M., Flannagan, K., Rhim, A. D., Simeone, D. M., Beatty, G. L., & Pasca di Magliano, M. (2017) · Gut · doi:10.1136/gutjnl-2016-312078 · Cited by 337
Circulating miRNAs: Roles in cancer diagnosis, prognosis and therapy
Cheng, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.001 · Cited by 334
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 321
Bernhardt, S. L., Gjertsen, M. K., Trachsel, S., Møller, M., Eriksen, J. A., Meo, M., Buanes, T., & Gaudernack, G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603437 · Cited by 305
CD40 stimulation obviates innate sensors and drives T cell immunity in cancer
Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · cited 6×
“Other APC agonists under investigation include toll like receptor (TLR) [74,75] and STING [76] agonists, which activate dendritic cells to improve T-cell priming.”
InfluentialSelf-citationA systematic review of humoral immune responses against tumor antigens
Reuschenbach, M., von Knebel Doeberitz, M., & Wentzensen, N. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0733-4 · Cited by 280
Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers
Kim, J., Bamlet, W. R., Oberg, A. L., Chaffee, K. G., Donahue, G., Cao, X.-J., Chari, S., Garcia, B. A., Petersen, G. M., & Zaret, K. S. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5583 · Cited by 269
Kimura, T., McKolanis, J. R., Dzubinski, L. A., Islam, K., Potter, D. M., Salazar, A. M., Schoen, R. E., & Finn, O. J. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0275 · Cited by 263
Le, D. T., Picozzi, V. J., Ko, A. H., Wainberg, Z. A., Kindler, H., Wang-Gillam, A., Oberstein, P., Morse, M. A., Zeh, H. J., Weekes, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2992 · Cited by 260
Chao, T., Furth, E. E., & Vonderheide, R. H. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0188 · Cited by 246
Self-citationImmune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer
Balli, D., Rech, A. J., Stanger, B. Z., & Vonderheide, R. H. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2128 · Cited by 235
Self-citationDetection of Circulating Pancreas Epithelial Cells in Patients With Pancreatic Cystic Lesions
Rhim, A. D., Thege, F. I., Santana, S. M., Lannin, T. B., Saha, T. N., Tsai, S., Maggs, L. R., Kochman, M. L., Ginsberg, G. G., Lieb, J. G., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.007 · Cited by 230
CAR T‐cell therapy of solid tumors
Yong, C. S. M., Dardalhon, V., Devaud, C., Taylor, N., Darcy, P. K., & Kershaw, M. H. (2017) · Immunology & Cell Biology · doi:10.1038/icb.2016.128 · Cited by 220
Shi, C., Hruban, R. H., & Klein, A. P. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.3.365 · Cited by 212
Hypermutation In Pancreatic Cancer
Humphris, J. L., Patch, A.-M., Nones, K., Bailey, P. J., Johns, A. L., McKay, S., Chang, D. K., Miller, D. K., Pajic, M., Kassahn, K. S., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.060 · Cited by 209
Hardacre, J. M., Mulcahy, M., Small, W., Talamonti, M., Obel, J., Krishnamurthi, S., Rocha-Lima, C. S., Safran, H., Lenz, H.-J., & Chiorean, E. G. (2013) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-012-2064-6 · Cited by 208
Stromnes, I. M., Schmitt, T. M., Hulbert, A., Brockenbrough, J. S., Nguyen, H. N., Cuevas, C., Dotson, A. M., Tan, X., Hotes, J. L., Greenberg, P. D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.022 · Cited by 200
Inflammatory networks and immune surveillance of pancreatic carcinoma
Vonderheide, R. H., & Bayne, L. J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.01.006 · Cited by 200
Self-citationT-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
Stromnes, I. M., Hulbert, A., Pierce, R. H., Greenberg, P. D., & Hingorani, S. R. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0322 · Cited by 197
Abate-Daga, D., Lagisetty, K. H., Tran, E., Zheng, Z., Gattinoni, L., Yu, Z., Burns, W. R., Miermont, A. M., Teper, Y., Rudloff, U., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.209 · Cited by 191
Lepisto, A. J., Moser, A. J., Zeh, H. J., Lee, K., Bartlett, D. L., McKolanis, J., Geller, B. A., Schmotzer, A. R., Potter, D. P., Whiteside, T. L., et al. (2008) · PubMed · Cited by 189
Predina, J., Eruslanov, E., Judy, B., Kapoor, V., Cheng, G., Wang, L.-C., Sun, J., Moon, E. K., Fridlender, Z. G., Albelda, S., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211850110 · Cited by 188
Wedén, S., Klemp, M., Gladhaug, I. P., Møller, M., Eriksen, J. A., Gaudernack, G., & Buanes, T. (2011) · International Journal of Cancer · doi:10.1002/ijc.25449 · Cited by 183
Foote, J. B., Kok, M., Leatherman, J. M., Armstrong, T. D., Marcinkowski, B. C., Ojalvo, L. S., Kanne, D. B., Jaffee, E. M., Dubensky, T. W., & Emens, L. A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0284 · Cited by 170
Redmond, W. L., Linch, S. N., & Kasiewicz, M. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0031-t · Cited by 168
Strategies for Increasing Pancreatic Tumor Immunogenicity
Johnson, B. A., Yarchoan, M., Lee, V., Laheru, D. A., & Jaffee, E. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2318 · Cited by 165
Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development
Dreyer, S. B., Chang, D. K., Bailey, P., & Biankin, A. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2411 · Cited by 162
Wiehagen, K. R., Girgis, N. M., Yamada, D. H., Smith, A. A., Chan, S. R., Grewal, I. S., Quigley, M., & Verona, R. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0258 · Cited by 162
Shrimali, R. K., Ahmad, S., Verma, V., Zeng, P., Ananth, S., Gaur, P., Gittelman, R. M., Yusko, E., Sanders, C., Robins, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0292 · Cited by 161
Lo, A., Li, C.-P., Buza, E. L., Blomberg, R., Govindaraju, P., Avery, D., Monslow, J., Hsiao, M., & Puré, E. (2017) · JCI Insight · doi:10.1172/jci.insight.92232 · Cited by 160
Chmielewski, M. M., Hahn, O., Rappl, G., Nowak, M. A., Schmidt‐Wolf, I. G. H., Hombach, A. A., & Abken, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.037 · Cited by 154
Keenan, B. P., Saenger, Y. M., Kafrouni, M. I., Leubner, A., Lauer, P., Maitra, A., Rucki, A. A., Gunderson, A. J., Coussens, L. M., Brockstedt, D. G., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.02.055 · Cited by 150
Mehrotra, S., Britten, C. D., Chin, S. H., Garrett-Mayer, E. S., Cloud, C. A., Li, M., Scurti, G. M., Salem, M. L., Nelson, M. H., Thomas, M. B., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0459-2 · Cited by 146
Chapuis, A. G., Roberts, I. M., Thompson, J. A., Margolin, K. A., Bhatia, S., Lee, S. M., Sloan, H. L., Lai, I. P., Farrar, E. A., Wagener, F. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.5142 · Cited by 127
CAR T‐cell therapy for pancreatic cancer
DeSelm, C. J., Tano, Z. E., Varghese, A. M., & Adusumilli, P. S. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24627 · Cited by 124
Winter, J. M., Tang, L. H., Klimstra, D. S., Brennan, M. F., Brody, J. R., Rocha, F. G., Jia, X., Qin, L., D'Angelica, M. I., DeMatteo, R. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040157 · Cited by 123
Toubaji, A., Achtar, M. S., Provenzano, M., Herrin, V. E., Behrens, R. J., Hamilton, M., Bernstein, S. A., Venzon, D. J., Gause, B. L., Marincola, F. M., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0477-6 · Cited by 122
Parente‐Pereira, A. C., Burnet, J., Ellison, D. H., Foster, J., Davies, D. M., van der Stegen, S. J. C., Papa, S., Chiapero-Stanke, L., Wilkie, S., Mather, S. J., et al. (2011) · Journal of Clinical Immunology · doi:10.1007/s10875-011-9532-8 · Cited by 118
Targeting Mutated K-ras in Pancreatic Adenocarcinoma Using an Adjuvant Vaccine
Abou‐Alfa, G. K., Chapman, P. B., Feilchenfeldt, J. W., Brennan, M. F., Capanu, M., Gansukh, B., Jacobs, G., Levin, A. R., Neville, D. A., Kelsen, D. P., et al. (2010) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e3181e84b1f · Cited by 111
Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer
Cappello, P., Rolla, S., Chiarle, R., Principe, M., Cavallo, F., Perconti, G., Feo, S., Giovarelli, M., & Novelli, F. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.020 · Cited by 110
Prevalence of Microsatellite Instability in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Lupinacci, R. M., Goloudina, A. R., Buhard, O., Bachet, J., Maréchal, R., Demetter, P., Cros, J. F., Bardier–Dupas, A., Collura, A., Cervera, P., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.11.009 · Cited by 109
Luheshi, N., Ulrichsen, J. C., Harper, J. A., Mullins, S., Sulikowski, M., Martin, P., Brown, L., Lewis, A. R., Davies, G. C., Morrow, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7610 · Cited by 105
Maliar, A., Servais, C., Waks, T., Chmielewski, M. M., Lavy, R., Altevogt, P., Abken, H., & Eshhar, Z. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.017 · Cited by 98
Mayanagi, S., Kitago, M., Sakurai, T., Matsuda, T., Fujita, T., Higuchi, H., Taguchi, J., Takeuchi, H., Itano, O., Aiura, K., et al. (2015) · Cancer Science · doi:10.1111/cas.12621 · Cited by 90
Jacobs, C., Duewell, P., Heckelsmiller, K., Wei, J., Bauernfeind, F. G., Ellermeier, J., Kisser, U., Bauer, C. A., Dauer, M., Eigler, A., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25399 · Cited by 89
Immunotherapy in pancreatic cancer treatment: a new frontier
Thind, K., Padrnos, L. J., Ramanathan, R. K., & Borad, M. J. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16667909 · Cited by 85
The pancreatic cancer microenvironment: A true double agent
Melstrom, L. G., Salazar, M. D., & Diamond, D. J. (2017) · Journal of Surgical Oncology · doi:10.1002/jso.24643 · Cited by 85
Miyazawa, M., Katsuda, M., Maguchi, H., Katanuma, A., Ishii, H., Ozaka, M., Yamao, K., Imaoka, H., Kawai, M., Hirono, S., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30510 · Cited by 80
Manuel, E. R., Chen, J., D’Apuzzo, M., Lampa, M. G., Kaltcheva, T. I., Thompson, C. B., Ludwig, T., Chung, V. M., & Diamond, D. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0214 · Cited by 72
Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival
Yuan, C., Qian, Z. R., Babić, A., Morales‐Oyarvide, V., Rubinson, D. A., Kraft, P. L., Ng, K., Bao, Y., Giovannucci, E. L., Ogino, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.3005 · Cited by 52
Reuschenbach, M., Kloor, M., Morak, M., Wentzensen, N., Germann, A., Garbe, Y., Tariverdian, M., Findeisen, P., Neumaier, M., Holinski‐Feder, E., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9307-z · Cited by 51
Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma
Szafranska-Schwarzbach, A. E., Adai, A. T., Lee, L., Conwell, D. L., & Andruss, B. F. (2011) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.11.10 · Cited by 45
Le, D. T., Ko, A. H., Wainberg, Z. A., Picozzi, V. J., Kindler, H. L., Wang‐Gillam, A., Oberstein, P. E., Morse, M. A., Zeh, H. J., Weekes, C. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.345 · Cited by 45
Chu, N. J., Armstrong, T. D., & Jaffee, E. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1186 · Cited by 43
Silva, A., Mount, A. M., Krstevska, K., Pejoski, D., Hardy, M. P., Owczarek, C. M., Scotney, P. D., Maraskovsky, E., & Morelli, A. B. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402228 · Cited by 36
Hingorani, S. R., Bullock, A. J., Seery, T. E., Zheng, L., Sigal, D. S., Ritch, P. S., Braiteh, F. S., Zalupski, M. M., Bahary, N., Harris, W. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4008 · Cited by 35
Cited by
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544
Self-citationOrth, M., Metzger, P., Gerum, S., Mayerle, J., Schneider, G., Belka, C., Schnurr, M., & Lauber, K. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1345-6 · Cited by 490
Zhou, W., Zhou, Y., Chen, X., Ning, T., Chen, H., Guo, Q., Zhang, Y., Liu, P., Zhang, Y., Li, C., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120546 · Cited by 425
Cui Zhou, D., Jayasinghe, R. G., Chen, S., Herndon, J. M., Iglesia, M. D., Navale, P., Wendl, M. C., Caravan, W., Sato, K., Storrs, E., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01157-1 · Cited by 284
Metadata
- Authors
- Morrison, A. H., Byrne, K. T., & Vonderheide, R. H.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2018-06
- Volume
- 4
- Issue
- 6
- Pages
- 418-428
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W2799466853
- Cited by
- 464
- References
- 115
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.